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Abstract 
Background: Ovarian cancer is the fifth leading cause of cancer death among women in the United 
States (US).  This study reports ovarian cancer survival by state, race and stage at diagnosis using data 
from the CONCORD-2 study, the largest and most geographically-comprehensive population-based 
survival study to date.   
Methods:  We used data from females diagnosed with ovarian cancer between 2001 and 2009 from 37 
states, covering 80% of the US population. We estimated survival up to 5 years, which was adjusted for 
background mortality (net survival) using state- and race-specific life tables and age-standardized.  
Results:  Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than half were 
diagnosed at distant stage.  Five-year net survival was 39.6% from 2001-2003 and 41.0% from 2004-
2009.  Black women had consistently worse survival compared to white women (29.6% from 2001-2003 
and 31.1% from 2004-2009), despite similar stage distributions.  Stage-specific survival for all races 
combined from 2004-2009 was 86.4% for localized stage, 60.9% for regional stage, 27.4% for distant 
stage.   
Conclusion:   Our data show a large and consistent disparity in ovarian cancer survival among black 
women compared to white women in most states.  Clinical efforts and public health efforts that ensure 
all women diagnosed with ovarian cancer receive appropriate guidelines-based treatment may help to 
decrease these disparities.  Future research that focuses on the development of new methods or 
modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve 
overall US ovarian cancer survival.     
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Introduction  
Ovarian cancer is the eighth most commonly diagnosed and fifth leading cause of cancer death in 
the United States (US).1  Ovarian cancer is a heterogeneous disease, consisting of epithelial and non-
epithelial types and subtypes.  Because of their similarity to epithelial ovarian cancer in terms of 
histology, pathogenesis and clinical disease course, primary fallopian tube and primary peritoneal 
cancers are often included in analyses of ovarian cancer.2   
Population-based ovarian cancer incidence and mortality (the number of new cases and deaths in 
a given time period, respectively) are presented annually in several reports.1, 3, 4 These reports show that 
age-standardized ovarian cancer incidence and death rates are highest among white women in the United 
States.1, 3, 4 Population-based survival is less often reported, and reflects the average survival for all 
cancer patients in the population, regardless of their age, sex, race, health status, clinical disease 
characteristics (e.g. stage of disease), socioeconomic status, residence at diagnosis or access to care.5  As 
such, population-based cancer survival provides an indicator of the overall effectiveness of the 
healthcare system to deliver cancer screening (if available), early diagnosis, and evidence-based 
treatment services and follow-up care to all people in the population being served.5  Population-based 
survival estimates also allow cancer control practitioners to identify target populations for educational 
interventions and environmental and health-systems changes that could help cancer patients lead longer, 
healthier lives.     
In the US, information on population-based ovarian cancer survival has come from individual 
state reports and from the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End 
Results (SEER) Program (covering 9-26% of the US population)3.  Additional non-population-based 
survival reports come from individual hospitals or institutions, or the National Cancer Database, which 
consists only of hospitals accredited by the Commission on Cancer.6  More recently, the Centers for 
Disease Control and Prevention’s (CDC) National Program of Cancer Registries (NPCR) has begun to 
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collect high quality survival data.7  Combined, SEER and NPCR data represent the official US federal 
government statistics on cancer.8   
The CONCORD-2 study collaborated with SEER and NPCR cancer registries, along with other 
population-based cancer registries around the world, to establish surveillance of cancer survival for ten 
common cancers from 67 countries.9  CONCORD-2 findings showed that for women diagnosed between 
1995 and 2009, international differences in ovarian cancer 5-year age-standardized net survival were 
wide, even after adjustment for differences in mortality from other causes of death, with survival in the 
United States improving and among the highest in the world.9   
The objective of this report is to extend the CONCORD-2 international study, as well as official 
US government annual reports of cancer incidence and mortality, to provide population-based ovarian 
cancer survival estimates for 37 US states.  This is the largest population-based ovarian cancer survival 
study in the US to date, covering 80% of the US population, and provides critical information for 
directing the state-specific ovarian cancer efforts of the National Comprehensive Cancer Control 
Program (NCCCP).    
Methods 
A detailed description of data sources, evaluation methods and statistical analyses can be found 
elsewhere in this Supplement.10  A brief description follows.   
Data Source and Variables 
We used data from the 37 NPCR or SEER state-wide cancer registries that participated in the 
CONCORD-2 study,9 covering approximately 80% of the US population, and consented to inclusion of 
their data in the more detailed analysis reported here.  We analyzed 172,849 individual tumor records for 
females (aged 15-99 years) who were diagnosed between 2001 and 2009 (and followed through to 
December 31, 2009) with cancer of the ovary, fallopian tube, peritoneum and retroperitoneum 
(henceforth referred to as ovarian cancer)  [ICD-O-3 codes11 for the tumors included in this analysis are 
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C48.0–C48.2, C56.9, C57.0–C57.4, C57.7–C57.9].9   Malignant tumors of uterine ligaments, and those 
from other and unspecified female genital organs were included in this analysis according to the 
CONCORD-2 protocol as to allow for comparison of survival data across all registries in the 
CONCORD-2 study.9  We included only the first primary, malignant cancer of the ovary, regardless of 
whether a woman had a previous cancer from a different site.  Any subsequent ovarian cancer diagnoses 
from 2001 through 2009 were excluded.  All benign and borderline tumors of the ovary were excluded; 
all malignant ovarian tumors (including epithelial and non-epithelial tumors) were included.  
We grouped patients by year of diagnosis into two calendar periods (2001-2003 and 2004-2009) 
to reflect changes in staging methods used by US cancer registries to collect SEER Summary Stage 2000 
(SS2000) at diagnosis.  SS2000 is the long-standing staging system routinely used by all US cancer 
registries and  broadly categorizes malignant tumors into localized, regional, distant, and unstaged to 
allow overall population-based reporting of staging trends.12  From 2001-2003, cancer registries directly 
coded SEER Summary Stage 2000 from the medical record, while from 2004-2009 all registries derived 
SS2000 using a series of data elements collected from the Collaborative Staging System.13  The derived 
SS2000 maintains the same stage categorization, but generally results in fewer cases staged as unknown 
due to the collection of a series of individual data elements related to disease extent and the use of rule-
based algorithms to assign a stage from those elements. 
All cancer registry data used in this analysis are high-quality, as assessed by the United States 
Cancer Statistics Working Group1 and the North American Association of Central Cancer Registries 
(NAACCR).14  All SEER and NPCR registries use the same, standardized procedures to collect the 
majority of information on cancer cases.10  However, SEER registries conduct both active and passive 
follow-up to ascertain vital status, while NPCR registries only conduct passive follow-up through 
linkages with their state vital records and the National Death Index to obtain information on deaths that 
occurred within their state and elsewhere within the United States.14      
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Survival Analyses 
We analysed ovarian cancer survival by state, race (all races combined, black, and white), 
SS2000, and calendar period of diagnosis (2001-2003 and 2004-2009).  The all races combined category 
includes all ovarian cancer cases in the dataset (black, white, and women of other or unspecified race). 
We estimated net survival up to 5 years after diagnosis with 95% confidence intervals (CI) using the 
Pohar Perme estimator.15  Net survival is interpreted as the probability of survival up to a given time 
since diagnosis, after controlling for other causes of death (background mortality).  To control for wide 
differences in background mortality among participating registries, we constructed life tables based on 
published methods16 of all-cause mortality in the general population of each state from the number of 
deaths and the populations, by single year of age, sex, calendar year and, where possible by race (white, 
black), using a flexible Poisson model.17 
We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since 
all patients were followed for at least five years by December 31, 2009.  We used the complete approach 
to estimate net survival for patients diagnosed from 2004-2009, because five years of follow-up data 
were not available for all patients from this calendar period.  Net survival was estimated for five age 
groups (15-44, 45-54, 55-64, 65-74, 75-99 years).  We obtained age-standardized survival estimates 
using the International Cancer Survival Standard (ICSS) weights.18  If two or more of the five age-
specific estimates could not be obtained, only the pooled, unstandardized survival estimate for all ages 
combined was presented.  Unstandardized survival estimates are italicized in Supplemental Tables 
showing state-specific data.  Trends, geographic variations and differences in age-standardized survival 
by race are presented graphically and in funnel plots.19  Funnel plots of net survival in the US by race 
and state show how much a particular survival estimate deviates from the pooled US estimate, given it’s 
level of  precision.  More information on these methods can be found in this Supplement.10  
Results 
7 
 
Of the 172,849 cancer cases included in this analysis, 56,390 women were diagnosed in 2001-
2003, and 116,459 in 2004-2009 (Table 1).  Over 85% of diagnoses were among white women during 
both time periods (49,893 from 2001-2003 and 101,717 from 2004-2009) and more than half of all cases 
(53.5% from 2001-2003 and 56.8% from 2004-2009) were diagnosed at distant stage, with minimal 
variability in stage distribution by race.  State-specific patterns mirrored national patterns in that there 
were much higher numbers of cases among white women compared to black women, and cases were 
most often diagnosed at distant stage (Supporting Table 1).   
Table 2 shows ovarian cancer age-standardized net survival at 1, 3, and 5 years for ovarian 
cancer by time period and race.  In both calendar periods, survival decreased with increasing time since 
diagnosis.  Between 2004 and 2009, survival was 73.3% (CI:73.0-73.6) at 1-year, 52.8% (CI:52.4-53.1) 
at 3-years, and 41.0% (CI:40.5-41.5) at 5-years.  Five-year survival was at least 10% lower in black 
women compared to white women in both calendar periods (29.6% [CI:28.1-31.1] compared to 40.1% 
[CI:39.6-40.6] in 2001-2003 and 31.1% [CI:29.5-32.7] compared to 41.7% [CI:41.2-42.2)] in 2004-
2009).  The racial gap appeared within the first year after diagnosis and persisted between the two 
calendar periods. Similar patterns were observed in most states (Supporting Table 2).    
Table 3 shows 5-year age-standardized net survival by race, stage at diagnosis and calendar 
period.  For all races combined, stage-specific survival improved between calendar periods; however, 
black women had lower survival compared to white women at each stage at diagnosis.  In the most 
recent calendar period, survival was highest for localized stage (86.4% [CI:84.8-87.9], followed by 
regional stage (60.9% [CI:59.7-62.2], and distant stage (27.4% [CI:26.9-28.0].  Similar patterns were 
observed in most states (Supporting Table 3).   
Figure 1 shows the absolute change in ovarian cancer survival from 2001-2003 to 2004-2009.  
Overall, 5-year net ovarian cancer survival increased 1.5% between 2001-2003 and 2004-2009.  Among 
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states, 27 had increases while 10 had decreases in survival between the two calendar periods.  In about 
half of states (18 of 37), the increase or decrease was less than or equal to 1.5%.   
Funnel plots showing 5-year age-standardized net ovarian cancer survival by race are presented 
in Figure 2.  Between 2001 and 2003, the age-standardized estimates for white women ranged from 
29.3% to 46.8% and between 2004 and 2009 the range was 33.1% to 51.4%.  In the first calendar period, 
all survival estimates for white women were within the control limits (no more than two or three 
standard deviations below or above the target of the pooled US all races combined estimate of 39.6%, 
after controlling for precision).  The same pattern was observed in 2004-2009, with estimates within the 
control limits around the pooled US estimate of 41.0%; however, in this time period, survival for white 
women in one state improved to a level above these limits.  Survival among black women ranged from 
24.4% to 33.1% in 2001-2003 and 16.5% to 41.7% in 2004-2009.  In both calendar periods, survival for 
black women was consistently lower in all states than that of the pooled US all races combined estimate 
and the majority were outside the control limits.    
Discussion 
Findings from this large population-based study show that US net survival from ovarian cancer is 
moderate overall, at about 40-41% survival at 5 years.  We have also shown a modest increase in 
survival in the most recent time period examined.  The data presented here show a consistent and 
persistent disparity in ovarian cancer survival among black women compared to white women.   
Our overall US survival estimates are somewhat lower than those from US analyses including 
only SEER registries, which are reported to be 44% survival at five years. With regard to trends, our 
findings are generally consistent with a recent SEER registry analysis that reported increases in ovarian 
cancer survival since 1990.  NPCR cancer registries contain an older and more rural population than 
SEER alone, which is a sample population that tends to be more urban and affluent than the general 
population.8 Several smaller studies have shown that older populations have lower survival from ovarian 
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cancer, potentially due to the existence of comorbidities or lack of access to care and other resources.20, 
21    Therefore, the greater inclusion of data from these older individuals likely underlies the somewhat 
lower survival estimates we report in this comprehensive study.  Given the passive only follow-up 
procedures of NPCR registries, NPCR registries may miss some deaths, particularly for patients who 
leave the United States between the time of their diagnosis and death, or those with incomplete 
demographic variables available for matching; this may result in a slight overestimation of survival 
rates.14  Therefore, the lower survival estimates observed here are likely true reflections of the broader 
inclusion of the population with ovarian cancer and not due to differences in vital status follow-up 
procedures.  Internationally, the ovarian cancer survival estimates reported here are similar to those 
countries with relatively higher estimates of ovarian cancer survival from the CONCORD-2 study, and 
are slightly higher than those reported from Canada (37.5% 5-year survival from 2005-2009).9   
Our finding that black women have consistently lower ovarian cancer survival than white women 
likely reflects a true and widespread racial disparity in ovarian cancer survival, given our inclusion of 
80% of the US population.  There is general inconsistency among published studies with regard to race-
specific ovarian cancer survival.  Some articles reported lower survival among black women compared 
to whites,6, 22-26 while others reported no difference.27-29  Additionally, a meta-analysis of pooled 5-year 
survival results from eight studies (106,704 women) found no difference in survival between black and 
white women.30  Because ovarian cancer is diagnosed in much greater numbers among white women 
than black women, a large study sample size is important in ovarian cancer studies stratified by race.  
Many smaller studies may not have had enough power to detect a difference in survival between black 
and white women.  Since our data include almost 14,000 cases of ovarian cancer among US black 
women, it is likely that our findings represent a true and widespread racial disparity in ovarian cancer 
survival.   
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The fact that ovarian cancer 5-year net survival is moderate and has not changed considerably 
over time is likely due to most cases continuing to be diagnosed at distant stage.  The preponderance of 
late-stage diagnoses contributes to ovarian cancer being described as a particularly deadly disease31; 
however, localized and regional stage diagnoses have relatively good survival overall,32, 33and stage-
specific ovarian cancer survival is similar to that of breast and uterine cancers.3  The differences in stage 
distribution seen among these three cancers is likely due to the availability of early detection methods 
for breast cancer34 and the presence of gynecologic-specific symptoms such as post-menopausal vaginal 
bleeding for uterine cancer.35  While US studies have been conducted to develop effective early 
detection methods for ovarian cancer, none have been found to provide a shift to earlier stage at 
diagnosis36, 37 or an overall mortality benefit,38and some have been shown to cause significant harms to 
women (mainly associated with unnecessary surgery).38  Recent results from a UK ovarian cancer 
screening trial have demonstrated more encouraging results with regard to detection of ovarian cancer at 
earlier stage39, 40; however, a reduction in mortality from ovarian cancer has not yet been observed in 
this trial.41  Continued follow-up of these trial participants, as well as positive evidence from other 
screening studies, is necessary before any changes in the current state of ovarian cancer screening 
among US women may be considered.  In lieu of evidence-based screening, symptom recognition may 
assist with early detection of ovarian cancer.42  Several studies have examined and defined the presence 
of a specific set of symptoms that occur in a majority of women prior to an ovarian cancer diagnosis.43, 
44  These symptoms, including bloating, pelvic pain, change in urination frequency and/or intensity, and 
early satiety after eating, often go unrecognized by women due to their non-gynecologic nature.  They 
can also be associated with other existing conditions, and women may not immediately seek care for 
such symptoms, which can prolong the time to diagnosis.45, 46  Increased public education regarding 
ovarian cancer symptom recognition and prompt care-seeking for those symptoms may help with 
increasing early stage diagnoses, resulting in increases in ovarian cancer survival.     
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Clinical Implications  
While effective early detection methods that reduce ovarian cancer mortality have yet to be 
developed, guidelines-based treatment protocols for ovarian cancer are well-established and adherence 
to these protocols leads to better surgical outcomes and improved survival among all ovarian cancer 
patients in the United States.  Several patient factors are consistently associated with not receiving 
recommended treatment, including older age, black race, the presence of co-morbid conditions, and low 
socioeconomic status.20, 47-50  In contrast, being treated at a high-volume facility, an NCI-designated 
cancer center, or by a gynecologic oncologist have been consistently associated with receiving 
guidelines-based, recommended treatment.47, 51-54 The fact that black women have been consistently 
shown to not receive guidelines-based treatment compared to white women, even when treated within 
the same hospital,26 likely contributes to lower survival seen in this study among black women.  It is 
unclear why black women are not receiving guidelines-based treatment; however, it is possible that 
difficulty in accessing particular hospitals or physicians may play a role.  Geographic disparities in 
ovarian cancer care have been well-documented, 55-58and a recent study in one urban NCI-designated 
cancer center showed that the farther gynecologic cancer patients were required to travel to get to 
treatment (those traveling above 10 but less than 50 miles), the less likely they were to complete 
recommended care.57  Patient influences may be another potential reason that black women may not be 
receiving guidelines-based care.  Fatalistic attitudes and mistrust of the medical system have been found 
to be more prevalent among black prostate cancer patients compared to white patients.59  These two 
factors along with negative beliefs about surgery are thought to explain almost one-third of the observed 
racial disparities in lung cancer treatment among black patients.60   Telemedicine, which would allow 
specialists to consult on patient cases remotely via phone- and/or video-conferencing, is an emerging 
area that may improve access to quality care in rural or underserved areas, and/or assist patients with 
being primarily cared for by a physician chosen and trusted by the patient.61   The utility of this method 
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for ovarian cancer in the United States is unknown however, and effective delivery of ovarian cancer 
surgical care, which is a key mediator of improved survival, is still being studied in telemedicine 
models.61  
Cancer Control Implications  
Public health efforts that educate women about ovarian cancer, and allow women to better 
navigate an ovarian cancer diagnosis more easily may assist with improvements in ovarian cancer 
survival.  CDC’s National Comprehensive Cancer Control Program (NCCCP) operates in all 50 states, 
the District of Columbia, 7 tribal governments and organizations, and 7 territories and US-associated 
Pacific Island jurisdictions to support the development and implementation of evidence-based initiatives 
to prevent and control cancer.62  Recent studies have documented prior ovarian cancer activities of the 
NCCCP; nearly half of programs are undertaking activities related to ovarian cancer, which largely 
center on education, primary prevention, and implementation of interventions to improve ovarian cancer 
survivors’ well-being.63, 64 Primary prevention activities include promoting smoking cessation and 
smoke-free environments as smoking is a risk factor for some types of ovarian cancer65, as well as the 
promotion of breastfeeding among women who have the opportunity, which several studies have 
suggested reduces risk for epithelial ovarian cancer.66  Several NCCCP grantees have partnered with 
CDC’s Inside Knowledge: Get the Facts about Gynecologic Cancer campaign67 to increase knowledge 
of other risk factors, symptoms, and recommendations for treatment of ovarian cancer among the public 
and providers.  These specific educational efforts are designed to reach and capture traditionally 
underserved populations in the United States, including black women.  Survivor interventions include 
developing patient navigation programs to assist cancer patients in seeking referrals and follow-up 
services, scheduling transportation to appointments, and improved communication with their providers 
among other activities.  These efforts may assist ovarian cancer patients with attending all scheduled 
medical appointments, which may result in longer disease-free intervals68 and improved survival.  Taken 
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together, these public health efforts have the potential of improving ovarian cancer survival among all 
women diagnosed in the United States, especially if adopted more widely by a majority of NCCCP 
grantees.   
This study is subject to some limitations.  First, the clinical utility of our analysis is limited, 
given results were not stratified by histologic type of ovarian cancer.  Due to the heterogeneity of 
ovarian cancer, survival varies widely both by histologic type (epithelial vs. non-epithelial)69 and 
subtype (e.g., serous adenocarcinoma vs. clear cell adenocarcinoma).70  Our analysis masked these 
differences.  Second, our high-level analysis does not consider factors known to influence survival from 
ovarian cancer including age, patient comorbidity status, and treatment.20, 53  Further, we include only 
SS2000, the registry staging system, as opposed to FIGO stage which is more commonly used in the 
clinic.  Balanced with these limitations are several strengths.  Our study was designed to be particularly 
useful for public health efforts.  This high-level analysis by state provides necessary data for resource 
allocation within health departments, and actionable items for the NCCCP in their efforts to help reduce 
the ovarian cancer burden.  It also reveals additional health inequities for all public health practitioners 
and stakeholders to address, and demonstrates the need for continued funding for ovarian cancer, since 
increases in survival have been modest in recent years.  Additionally, the rigorous quality control and 
statistical methods used ensure that only the highest quality data were included in this analysis.10  
Almost all cases included in this analysis were microscopically confirmed, further ensuring the high 
quality of the data.  Finally, our study includes data from a majority of US states, making it, to our 
knowledge, the largest and most geographically-comprehensive US ovarian cancer survival analysis.  
The inclusion of this large number of states allowed for adequate sample size to detect differences 
among racial populations.          
Conclusion 
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Ovarian cancer survival is moderate across the US; however, black women have consistently 
lower survival from this disease than white women.  Future research focusing on the development of 
new screening methods or modalities that lead to a greater number of earlier-stage diagnoses will likely 
improve overall ovarian cancer survival.  In the meantime, clinical efforts that ensure all women 
diagnosed with ovarian cancer receive appropriate guidelines-based treatment, and public health efforts 
that educate women about the risks factors, signs and symptoms of ovarian cancer may help to decrease 
current disparities in US ovarian cancer survival.   
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Table 1.  Ovarian cancer: Number of cases diagnosed among females aged 15-99 years, by stage at 
diagnosis and calendar period*, 2001-2009  
 2001-2003 2004-2009 
SS2000* 
 
All races White Black All races White Black 
No. of 
patients 
 
56,390 49,893 4,262 116,459 101,717 9,440 
Localized (%) 15.9 15.7 15.4 14.2 13.9 14.5 
Regional  (%) 18.9 18.9 16.4 18.9 19.0 15.7 
Distant (%) 53.5 54.1 51.0 56.8 57.4 55.3 
Unknown (%) 11.7 11.3 17.2 10.1 9.7 14.5 
*Stage at diagnosis is SEER Summary Stage 2000 (SS2000). 
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Table 2.  Ovarian cancer: Age-standardized net survival (NS %) at 1, 3, and 5 years among females aged 
15-99 years, by race and calendar period, 2001-2009 
 
  
 2001-2003 2004-2009  
All races White Black All races White Black 
Years NS 
(%)  
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(
%
) 
95% CI 
1 72.3 71.
9 
- 72.
7 
73.
3 
72.
9 
- 73.
7 
59.
8 
58.
2 
- 61.
3 
73.
3 
73.
0 
- 73.
6 
74.
2 
73.
9 
- 74.
5 
62.
5 
61.
4 
- 63.
6 
3 50.9 50.
4 
- 51.
3 
51.
6 
51.
1 
- 52.
1 
39.
4 
37.
8 
- 41.
0 
52.
8 
52.
4 
- 53.
1 
53.
6 
53.
2 
- 54.
0 
41.
6 
40.
3 
- 42.
9 
5 39.6 39.
1 
- 40.
0 
40.
1 
39.
6 
- 40.
6 
29.
6 
28.
1 
- 31.
1 
41.
0 
40.
5 
- 41.
5 
41.
7 
41.
2 
- 42.
2 
31.
1 
29.
5 
- 32.
7 
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Table 3.  Ovarian cancer: Five-year age-standardized net survival (NS %) among females aged 15-99 
years, by stage at diagnosis*, race, and calendar period, 2001-2009 
 
*Stage at diagnosis is SEER Summary Stage 2000 (SS2000). 
  
 2001-2003 2004-2009 
 All races White Black All races White Black 
SS2000* NS 
(%
)  
 NS 
(%)  
 NS 
(%
)  
 NS 
(%)  
 NS 
(%
)  
 NS 
(%
)  
 
All 
stages 
39.
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39.
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- 40.0 40.1 39.
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9 
52.
8 
- 55.1 54.7 53.
5 
- 55.9 38.
6 
34.
3 
- 42.9 60.9 59.
7 
- 62.2 61.
6 
60.
3 
- 62.
9 
45.
3 
40.
7 
- 49.
9 
Distant 25.
2 
24.
7 
- 25.7 25.8 25.
2 
- 26.4 16.
3 
14.
7 
- 18.0 27.4 26.
9 
- 28.0 28.
0 
27.
4 
- 28.
7 
18.
6 
16.
8 
- 20.
5 
Unknow
n 
33.
1 
31.
9 
- 34.4 33.7 32.
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Figure 1.  Ovarian cancer:  Five-year age-standardized net survival (%) among females aged 15-99 
years, and absolute change in net survival (%), by calendar period, 2001-2009 
 
 
 
Note: States are ranked within Census Region by the survival estimate for 2004-2009.  Dark colors are 
registries affiliated with the National Program of Cancer Registries (NPCR); pale colors are registries 
affiliated with the Surveillance, Epidemiology, and End Results (SEER) Program.  An asterisk (*) 
denotes registries affiliated with both programs.   
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Figure 2.  Ovarian cancer: Five-year age-standardized net survival (NS %) among females aged 15-99 
years, by state, race and calendar period of diagnosis 
 
FUNNEL PLOT to be inserted here 
 
Note: The pooled (US) survival estimates for each calendar period are shown by the horizontal (solid) 
line with corresponding 95.0% and 99.8% control limits (dotted lines).   
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Supporting Table 1.  Ovarian cancer: Number of cases diagnosed among females aged 15-99 years, by 
stage at diagnosis, calendar period, and US state (grouped by US Census Region)*, 2001-2009 
  
*Stage at diagnosis is SEER Summary Stage 2000 (SS2000).  Information on stage was not available for 
two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed from 2004-2009.    
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Supporting Table 2.  Ovarian cancer: Age-standardized net survival (NS %) at 1, 3, and 5 years among 
females aged 15-99 years, by race, calendar period, and US state (grouped by US Census Region), 2001-
2009 
 
Note: Unstandardized estimates are italicized. 
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Supporting Table 3.  Ovarian cancer: Five-year age-standardized net survival (NS %) among females 
aged 15-99 years, by stage at diagnosis*, race, calendar period, and US state (grouped by US Census 
Region), 2001-2009 
 
Note: *Stage at diagnosis is SEER Summary Stage 2000 (SS2000). Information on stage was not 
available for two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed from 2004-
2009.  Unstandardized estimates are italicized.   
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